Response to treatment. Response to treatment represented as (A) best response at any time point and at the primary end point of 4 months after CTL019 infusion and (B) MRD status in the 16 patients in CR at month 4 by PB immunophenotyping and immunoglobulin high-throughput sequencing in PB and bone marrow aspirate samples. N/A, not available; PD, progressive disease; PR, partial response; SD, stable disease.